Advertisement

Serotonergic Mechanisms in Myoclonus

  • J. H. Growdon
Conference paper
Part of the Journal of Neural Transmission book series (NEURAL SUPPL, volume 15)

Summary

Post-hypoxic intention myoclonus is a specific myoclonic syndrome in which central serotonergic tone may be deficient. Tryptophan and 5-hydroxytryptophan administration to patients with post-hypoxic intention myoclonus increases pre-existing low levels of 5-hydroxyindoleacetic acid levels in the cerebrospinal fluid, and also suppresses myoclonus. Serotonin precursor administration does not help all patients with myoclonus and may actually worsen some myoclonic syndromes, including those secondary to lipid storage diseases. Treatments that alter serotonin metabolism can also produce myoclonus in experimental animals but their relevance to myoclonic syndromes in humans remains uncertain.

Keywords

Serotonergic Mechanism Aromatic Amino Acid Decarboxylase Lipid Storage Disease Serotonin Deficiency Action Myoclonus 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bonduelle, M.: The Myoclonias. In: Handbook of Clinical Neurology (Vinken, P.J., Bruyn, G.W., eds.), Vol.6, Ch. 29, pp. 761–781. Amsterdam: North Holland. 1968.Google Scholar
  2. Castaigne, P., Cambier, J., Escourolle, R., Cathala, H. P., Lacasble, R.: Observation anatomo-clinique d’un syndrome myoclonique post-anoxique. Rev. Neurol. 111, 60–73 (1964).Google Scholar
  3. Chadwick, D., Jenner, P., Harris, R., Reynolds, E.H., Marsden, C.D.: Manipulation of brain serotonin in the treatment of myoclonus. Lancet 2, 434–435 (1975).PubMedCrossRefGoogle Scholar
  4. Chadwick, D., Hallett, M., Harris, R., Jenner, P., Reynolds, E. H., Marsden, C. D.: Clinical, biochemical, and physiological features distinguishing myoclonus responsive to 5-hydroxytryptophan, tryptophan with a monoamine oxidase inhibitor, and clonazepam. Brain 100, 455–487 (1977).PubMedCrossRefGoogle Scholar
  5. DeLean, J., Richardson, J. C, Hornykiewicz, O.: Beneficial effects of serotonin precursors in postanoxic action myoclonus. Neurology 26, 863–868 (1976).CrossRefGoogle Scholar
  6. Fernstrom, J.D., Wurtman, R. J.: Brain serotonin content: physiological regulation by plasma neutral amino acids. Science 178, 414–416 (1972).PubMedCrossRefGoogle Scholar
  7. Guilleminault, C., Tharp, B. R., Cousin, D.: HVA and 5-HIAA measurements and 5-HTP trials in some patients with involuntary movements. J. Neurol. Sci. 18, 435–441 (1973).PubMedCrossRefGoogle Scholar
  8. Grahame-Smith, D. G.: Studies in vivo on the relationship between brain tryptophan, brain 5-HT synthesis, and hyperactivity in rats treated with monoamine oxidase inhibitor and L-tryptophan. J. Neurochem. 18, 1053–1066 (1971).PubMedCrossRefGoogle Scholar
  9. Growdon, J. H., Young, R. R., Shahani, B. T.: L-5-hydroxytryptophan in treatment of several different syndromes in which myoclonus is prominent. Neurology 26, 1135–1140 (1976).PubMedCrossRefGoogle Scholar
  10. Growdon, J. H.: Postural changes, tremor, and myoclonus in the rat immediately following injections of p-chloroamphetamine. Neurology 27, 1074–1077 (1977).PubMedCrossRefGoogle Scholar
  11. Growdon, J. H.: Changes in motor behavior following the administration of serotonin neurotoxins. Annals N.Y. Acad. Sci. 305, 510–523 (1978).CrossRefGoogle Scholar
  12. Hallett, M., Marsden, C. D.: Ballistic movement overflow myoclonus. A form of essential myoclonus. Brain 100, 299–312 (1977).Google Scholar
  13. Halliday, A. M.: The clinical incidence of myoclonus. In: Modern Trends in Neurology (Williams, D., ed.), Vol. 4, pp. 69–105. London: Butterworth. 1967.Google Scholar
  14. Halliday, A. M.: The electrophysiological study of myoclonus in man. Brain 90, 241–284 (1967).PubMedCrossRefGoogle Scholar
  15. Jenner, P., Chadwick, D., Reynolds, E. H., Marsden, C. D.: Altered 5-HT metabolism with clonazepam and diphenylhydantoin. J. Pharm. Pharmacol. 27, 707–710 (1975).PubMedCrossRefGoogle Scholar
  16. Klawans, H. L., Goetz, C., Weiner, W. J.: 5-Hydroxytryptophan-induced myoclonus in guinea pigs and the possible role of serotonin in infantile myoclonus. Neurology 23, 1234–1240 (1973).PubMedCrossRefGoogle Scholar
  17. Lance, J. W., Adams, R. D.: The syndrome of intention or action myoclonus as a sequel to hypoxic encephalopathy. Brain 86, 111–136 (1963).PubMedCrossRefGoogle Scholar
  18. Lhermitte, F., Peterfalvi, M., Marteau, R., Gazengel, J., Serdaru, M.: Pharmacological analysis of a case of postanoxic intention and action myoclonus. Rev. Neurol. 124, 21–31 (1971).PubMedGoogle Scholar
  19. Lhermitte, F., Marteau, R., Degos, C. F.: Analyse pharmacologique d’un nouveau cas de myoclonies d’intention et d’action post-anoxiques. Rev. Neurol. 126, 107–114 (1972).PubMedGoogle Scholar
  20. Stewart, R. M., Growdon, J.H., Cancian, D., Baldessarini, R.J.: 5-hydroxy-tryptophan-induced myoclonus: increased sensitivity to serotonin after intracranial 5, 7-dihydroxytryptamine in the adult rat. Neuropharm. 15, 449–455 (1976).CrossRefGoogle Scholar
  21. Swanson, P. D., Luttrell, C. N., Magladery, J. W.: Myoclonus—a report of 67 cases and a review of the literature. Medicine 41, 339–356 (1962).PubMedCrossRefGoogle Scholar
  22. Trulson, M. D., Jacobs, B. L.: Behavioral evidence of the rapid release of CNS serotonin by PCA and fenfluoramine. Eur. J. Pharmacol. 36, 149–154 (1976).PubMedCrossRefGoogle Scholar
  23. Trulson, M. E., Eubanks, E. E., Jacobs, B. L.: Behavioral evidence for supersensitivity following destruction of central serotonergic nerve terminals by 5, 7-dihydroxytryptamine. J. Pharmacol. Exp. Ther. 198, 23–32 (1976).PubMedGoogle Scholar
  24. Van Woert, M. H., Hwang, E. C: Myoclonus: biochemical and pharmacological approaches. In: Clin. Neuropharm. Vol. 3 (Klawans, H. L., ed.). New York: Raven Press. 1978.Google Scholar
  25. Van Woert, M. H., Sethy, V. H.: Therapy of intention myoclonus with L-5-hydroxytryptophan and a peripheral decarboxylase inhibitor, MK 486. Neurol. 25, 135–140 (1975).CrossRefGoogle Scholar
  26. Van Woert, M. H., Jutkowitz, R., Rosenbaum, D., Bowers, M. B., jr.: Serotonin and myoclonus. Monogr. neural Sci. 3, 71–80 (1976).PubMedGoogle Scholar
  27. Van Woert, M. H., Rosenbaum, D., Howieson, J., Bowers, M. B., jr.: Longterm therapy of myoclonus and other neurologic disorders with L-5-hydroxytryptophan and carbidopa. N.E.J.M. 296, 70–75 (1977).CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Wien 1979

Authors and Affiliations

  • J. H. Growdon
    • 1
  1. 1.Department of NeurologyTufts-New England Medical Center HospitalBostonUSA

Personalised recommendations